Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Vemurafenib (Primary) ; Cobimetinib
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2018 Cobimetinib drug added to the study.
- 19 Jul 2016 Status changed from not yet recruiting to recruiting.
- 13 Jul 2016 New trial record